We are live on ! Find out more
BBIO icon

BridgeBio Pharma
BBIO

210 hedge funds and large institutions have $6.56B invested in BridgeBio Pharma in 2021 Q3 according to their latest regulatory filings, with 30 funds opening new positions, 83 increasing their positions, 61 reducing their positions, and 18 closing their positions.

New
Increased
Maintained
Reduced
Closed

67% more first-time investments, than exits

New positions opened: 30 | Existing positions closed: 18

36% more repeat investments, than reductions

Existing positions increased: 83 | Existing positions reduced: 61

5% more funds holding

Funds holding: 200 → 210 (+10)

0% more funds holding in top 10

Funds holding in top 10: 15 → 15 (0)

2.04% less ownership

Funds ownership: 95.52% → 93.48% (-2%)

22% less call options, than puts

Call options by funds: $19.6M | Put options by funds: $25M

22% less capital invested

Capital invested by funds: $8.46B → $6.56B (-$1.9B)

Holders
210
Holders Change
+10
Holders Change %
+5%
% of All Funds
3.68%
Holding in Top 10
15
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.26%
New
30
Increased
83
Reduced
61
Closed
18
Calls
$19.6M
Puts
$25M
Net Calls
-$5.4M
Net Calls Change
+$4.12M

Top Buyers

Rank Fund Capital Flow
1
BlackRock
BlackRock
New York
+$34.4M
2
Fisher Asset Management
Fisher Asset Management
Washington
+$30.5M
3
State Street
State Street
Massachusetts
+$23.1M
4
Charles Schwab
Charles Schwab
California
+$17.2M
5
Fidelity Investments
Fidelity Investments
Massachusetts
+$16.2M

Top Sellers

Rank Fund Capital Flow
1
Vanguard Group
Vanguard Group
Pennsylvania
-$102M
2
IAM
Iridian Asset Management
Connecticut
-$59.9M
3
EAM
Eventide Asset Management
Massachusetts
-$43.4M
4
APM
Avidity Partners Management
Texas
-$41M
5
T. Rowe Price Associates
T. Rowe Price Associates
Maryland
-$26.7M
Name Holding Trade Value Shares
Change 		Change in
Stake
GC
76
Grace Capital
Massachusetts
$3.99M +$268K +5,000 +6%
Deutsche Bank
77
Deutsche Bank
Germany
$3.95M -$13M -242,751 -74%
Legal & General Group
78
Legal & General Group
United Kingdom
$3.74M +$704K +13,140 +20%
ACM
79
Altium Capital Management
New York
$3.7M +$4.23M +79,000 New
SAM
80
Silvercrest Asset Management
New York
$3.46M +$1.47M +27,425 +59%
ACM
81
Atika Capital Management
New York
$3.45M +$59K +1,100 +2%
UBS AM
82
UBS AM
Illinois
$3.31M +$81.1K +1,513 +2%
PAMS
83
Pictet Asset Management (Switzerland)
Switzerland
$3.24M +$3.7M +69,071 New
Wells Fargo
84
Wells Fargo
California
$3.2M +$1.69M +31,585 +86%
HT
85
HAP Trading
New York
$3.16M +$1.62M +30,253 +82%
WCM Investment Management
86
WCM Investment Management
California
$3.07M +$25.8K +482 +0.7%
JG
87
Jefferies Group
New York
$3.02M -$8.36M -156,000 -71%
Rafferty Asset Management
88
Rafferty Asset Management
New York
$2.9M +$1.13M +21,078 +52%
PPA
89
Parametric Portfolio Associates
Washington
$2.89M +$234K +4,367 +8%
EAM
90
Erste Asset Management
Austria
$2.73M -$1.03M -19,200 -25%
PHP
91
Parkman Healthcare Partners
Connecticut
$2.72M – – –
PFC
92
Phocas Financial Corp
California
$2.65M +$31.3K +584 +1%
Manulife (Manufacturers Life Insurance)
93
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$2.64M -$279K -5,200 -8%
State of New Jersey Common Pension Fund D
94
State of New Jersey Common Pension Fund D
New Jersey
$2.62M +$606K +11,309 +25%
Invesco
95
Invesco
Georgia
$2.48M +$333K +6,207 +13%
PA
96
Pinnacle Associates
New York
$2.45M – – –
PWMAG
97
Pinnacle Wealth Management Advisory Group
New Jersey
$2.45M – – –
CAM
98
ClariVest Asset Management
California
$2.41M -$158K -2,945 -5%
RC
99
Renaissance Capital
Connecticut
$2.4M -$4.06M -75,814 -60%
GC
100
Guggenheim Capital
Illinois
$2.4M +$287K +5,350 +12%
2 3
4
5 6

BBIO Hedge Fund Activity: Q3 2021 in Review

210 of the 5,712 institutional investors tracked by Wall St. Rank reported a position in BridgeBio Pharma (BBIO) for Q3 2021, worth a combined $6.56B — down 22% from $8.46B a quarter earlier.

Buyers outnumbered sellers: 30 funds opened new BBIO positions and 18 closed out — a net gain of 12 holders — while 83 added to existing stakes and 61 trimmed.

The largest buyer was BlackRock, adding an estimated $34.4M. The largest seller was Vanguard Group, cutting an estimated $102M.

  • 210 institutional investors held BridgeBio Pharma (BBIO) as of Q3 2021, up from 200 in Q2 2021.
  • Funds reported $6.56B of BridgeBio Pharma stock for Q3 2021, down 22% quarter-over-quarter.
  • 30 funds opened new BridgeBio Pharma positions in Q3 2021 and 18 closed out, a net change of +12 holders.
  • The largest BridgeBio Pharma buyer in Q3 2021 was BlackRock, an estimated $34.4M added.
  • The largest BridgeBio Pharma seller in Q3 2021 was Vanguard Group, an estimated $102M sold.

Based on aggregated 13F filings for Q3 2021.